Indirect Treatment Comparison of Depemokimab Compared to Other Respiratory Biologics in Severe Asthma

Trial description: Depemokimab, a long-acting anti-interleukin (IL)-5 monoclonal antibody, is currently being assessed for the treatment of severe asthma with an eosinophilic phenotype despite treatment with standard of care (SoC). SWIFT 1 (206713) and 2 (213744), randomized, placebo-controlled, double-blind, parallel group design clinical trials, both demonstrated statistically significant and clinically meaningful reductions in exacerbations over 52 weeks compared to placebo. However, there is a need to understand how Depemokimab also compares to other biologic treatments for severe asthma. The objective of this study is to reduce uncertainty in the relative clinical effect and safety of Depemokimab versus relevant comparator respiratory biologics in participants with severe asthma. Anchored indirect treatment comparisons will be employed that collectively combine data across randomized clinical trials of Depemokimab (SWIFT 1 and SWIFT 2) and other relevant biologic treatments for severe asthma.